40 research outputs found

    Cytotoxicity and genotoxicity of chitooligosaccharides upon lymphocytes

    Get PDF
    Two COS mixtures and a low molecular weight chitosan (LMWC) were tested for potential cytotoxicity and genotoxicity upon human lymphocytes. Genotoxicity was evaluated in vitro by cytokinesis-blocked micronucleus and alkaline comet assays, while cytotoxicity was assessed by flow cytometry analysis. Our results suggest that COS do not exhibit any genotoxicity upon human lymphocytes, independently of MW or concentration. However, above 0.07 mg/mL COS induced strong cytotoxic effects. According to the concentration used, such cytotoxicity will induce cell death, essentially by necrosis (>0.10 mg/mL) and/or apoptosis (<0.10 mg/mL). The level of necrosis/apoptosis induced by high COS concentrations, suggests a promising use as apoptosis inducers in specific cancer situations.info:eu-repo/semantics/acceptedVersio

    Antioxidant activity of chitooligosaccharides upon two biological systems: erythrocytes and bacteriophages

    Get PDF
    Most of the reports to date on the antioxidant capacity of chitosans and chitooligosaccharides (COS) are based on strictly chemical methods. When studying antioxidants with potential in vivo applications, the method used to evaluate the antioxidant activity should be representative of the conditions in which the antioxidant might have a protective effect. In this work we evaluate the antioxidant activity of two COS mixtures and a low MW chitosan (LMWC) upon two biological oxidizable substrates – erythrocytes and phages, subjected to accelerated oxidation conditions. Our results suggest that COS/LMWC can be used as antioxidants in biological systems. All the tested compounds reduced either the hemolytic and DNA damage, by inhibiting H2O2- and AAPH-radicals. However, the results obtained for these biological assays did not reveal a dose dependence, contrary to the chemical assay, suggesting that the protective concentrations should be established, in order to prevent enhancement of the oxidative damage – i.e. a prooxidant effect.info:eu-repo/semantics/acceptedVersio

    Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

    Get PDF
    Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

    Dementia in Latin America : paving the way towards a regional action plan

    Get PDF
    Regional challenges faced by Latin American and Caribbean countries (LACs) to fight dementia, such as heterogeneity, diversity, political instabilities, and socioeconomic disparities, can be addressed more effectively grounded in a collaborative setting based on the open exchange of knowledge. In this work, the Latin American and Caribbean Consortium on Dementia (LAC-CD) proposes an agenda for integration to deliver a Knowledge to Action Framework (KtAF). First, we summarize evidence-based strategies (epidemiology, genetics, biomarkers, clinical trials, nonpharmacological interventions, networking and translational research) and align them to current global strategies to translate regional knowledge into actions with transformative power. Then, by characterizing genetic isolates, admixture in populations, environmental factors, and barriers to effective interventions and mapping these to the above challenges, we provide the basic mosaics of knowledge that will pave the way towards a KtAF. We describe strategies supporting the knowledge creation stage that underpins the translational impact of KtAF

    Absolute requirement of GDNF for adult catecholaminergic neuron survival

    Get PDF
    33 páginas, 7 figuras, 1 tabla.GDNF is a potent neurotrophic factor that protects catecholaminergic neurons from toxic damage and induces fiber outgrowth. However, the actual role of endogenous GDNF in the normal adult brain is unknown, even though GDNF-based therapies are considered promising for neurodegenerative disorders. We have generated a conditional GDNF-null mouse to suppress GDNF expression in adulthood, hence avoiding the developmental compensatory modifications masking its true physiologic action. After Gdnf ablation, mice showed a progressive hypokinesia and a selective decrease of brain tyrosine hydroxylase (Th) mRNA, accompanied by pronounced catecholaminergic cell death, affecting most notably the locus coeruleus, which practically disappears; the substantia nigra; and the ventral tegmental area. These data unequivocally demonstrate that GDNF is indispensable for adult catecholaminergic neuron survival and also show that, under physiologic conditions, downregulation of a single trophic factor can produce massive neuronal death.Support was obtained from the Juan March Foundation, the Marcelino Botín Foundation, the Spanish Ministry of Science and Education, the Spanish Ministry of Health (TERCEL), and the Andalusian Government. CIBERNED is funded by the “Instituto de Salud Carlos III”.Peer reviewe

    Differential impairment of catecholaminergic cell maturation and survival by genetic mitochondrial complex II dysfunction

    No full text
    The SDHD gene (subunit D of succinate dehydrogenase) has been shown to be involved in the generation of paragangliomas and pheochromocytomas. Loss of heterozygosity of the normal allele is necessary for tumor transformation of the affected cells. As complete SdhD deletion is lethal, we have generated mouse models carrying a >floxed> SdhD allele and either an inducible (SDHD-ESR strain) or a catecholaminergic tissue-specific (TH-SDHD strain) CRE recombinase. Ablation of both SdhD alleles in adult SDHD-ESR mice did not result in generation of paragangliomas or pheochromocytomas. In contrast, carotid bodies from these animals showed smaller volume than controls. In accord with these observations, the TH-SDHD mice had decreased cell numbers in the adrenal medulla, carotid body, and superior cervical ganglion. They also manifested inhibited postnatal maturation of mesencephalic dopaminergic neurons and progressive cell loss during the first year of life. These alterations were particularly intense in the substantia nigra, the most affected neuronal population in Parkinson's disease. Unexpectedly, TH + neurons in the locus coeruleus and group A13, also lacking the SdhD gene, were unaltered. These data indicate that complete loss of SdhD is not sufficient to induce tumorigenesis in mice. They suggest that substantia nigra neurons are more susceptible to mitochondrial damage than other catecholaminergic cells, particularly during a critical postnatal maturation period. © 2012, American Society for Microbiology.Support was obtained from the Marcelino Botín Foundation, the Spanish Ministries of Science and Health (TERCEL), and the Andalusian Government.Peer Reviewe

    Animal models for neurodegenerative diseases

    No full text
    38 páginas, 8 figuras, 1 tabla. Fecha de prioridad: 07/12/2007. IPC: A01K-067/00; A61K-049/00; C07K-014/00; C12N-015/00. Solicitante: Universidad de Sevilla.The invention provides a non-human animal model of Parkinson's disease based on animals which carry a modified version of the GDNF gene which comprises recombinase target sites flanking an essential part of said gene and a transgene which encodes for a recombinase specific for the target sites in the GDNF gene and which can be activated at will by administering a given compound to the animal. Activation of the recombinase in adult animals leads to a progressive catecholaminergic neuronal death. The invention also provides the use of said animals for the study of the pathogenesis of Parkinson's disease and for the identification of GDNF targets (which preserve the neurons from degeneration) as well as GDNF agonists and activators.Peer reviewe
    corecore